Mylan Stock Quote and Financials for Informed Investment Decisions

Mylan's stock price is listed on the NASDAQ stock exchange under the ticker symbol MYL. Mylan's stock price has been affected by its acquisition of Perrigo, which was completed in 2015.

Mylan's revenue has consistently increased over the years, with a significant jump in 2015 following the acquisition of Perrigo. The company's revenue has been driven by the growth of its generic and specialty pharmaceuticals business.

Mylan's net income has also seen a significant increase, reaching $2.8 billion in 2015. This increase in net income is a result of the company's ability to manage costs and drive growth through strategic acquisitions and partnerships.

Mylan's financials are quite impressive, with net sales reaching a high of $59.66 billion in 2024 and a low of $11.91 billion in the same year.

Their net income has also seen significant fluctuations, ranging from $207 million in 2024 to $39.97 billion in the same year.

Let's take a look at their net debt, which stood at $13.36 billion in 2024 and decreased to $9.38 billion in 2025.

Here's a breakdown of Mylan's financials over the years:

As for investments, Mylan has made 2 investments, with their latest being in Mapi Pharma as part of their Corporate Minority - II on April 27, 2018.

Mylan has made 2 investments, with their latest being in Mapi Pharma as part of their Corporate Minority - II on April 27, 2018. This investment was a significant move for the company, but let's take a closer look at their financials.

Their net sales have been steadily increasing over the years, with a notable jump in 2024 to $21.33B. This is a substantial growth from their 2023 sales of $11.91B. In contrast, their net income has fluctuated, with a peak of $39.97B in 2024 and a low of $207M in 2023.

Here's a breakdown of their net sales and net income for the past few years:

Their net debt has also been a concern, with a peak of $21.37B in 2024. However, their net debt has been decreasing in recent years, with a low of $9.38B in 2025.

Mylan has made a significant move in its portfolio, with a notable exit in 2023. One of its portfolio exits was with Famy Care on October 2, 2023.

The exit was a result of Mylan acquiring Famy Care for a valuation of $XXM. Insud Pharma was the acquirer in this deal.

Famy Care is just one example of a company that Mylan has exited its portfolio.

Technical analysis can be a powerful tool for understanding Mylan's stock performance. Mylan's technical indicators suggest a mixed picture.

The company's Risk Adjusted Performance is -0.04, indicating a relatively stable risk-adjusted return. Mylan's Jensen Alpha is -0.07, showing a negative alpha, which means the stock's return is lower than the market's return.

Total Risk Alpha is -0.15, indicating a higher risk-adjusted return than the market. The Treynor Ratio is 3.29, which is a measure of the excess return per unit of risk.

If you're looking for more insights, you can explore Mylan's various technical indicators, such as cycle indicators, momentum indicators, and volatility indicators. These can help you better understand the stock's performance and make more informed investment decisions.

Here are some key technical indicators for Mylan:

These technical indicators can be used to analyze Mylan's stock performance and make more informed investment decisions.

Mylan's valuation has been a topic of interest, with its market capitalization fluctuating between 10.96B and 21.8B. The company's enterprise value also shows a range, from 21.69B to 43.17B.

The P/E ratio for 2024 is estimated at 70.5x, while the P/E ratio for 2025 is expected to be 18.6x. Additionally, the EV/Sales ratio for 2024 is around 1.82x, and 1.76x for 2025.

Here is a breakdown of Mylan's valuation metrics:

Mylan's free-float yield is expected to be around 4.49% in 2024, and 4.61% in 2025.

The valuation of a company is a crucial aspect of its overall health and potential for growth. Mylan N.V. has a capitalization of $13.63B, which is a significant figure in the pharmaceutical industry.

The price-to-earnings (P/E) ratio is a key metric used to evaluate a company's stock performance. As of 2024, Mylan N.V.'s P/E ratio is 70.5x, while in 2025 it's expected to be 18.6x.

The enterprise value of a company is the total value of its debt and equity. Mylan N.V.'s enterprise value is $26.99B, which is a substantial amount for any company.

Here's a breakdown of Mylan N.V.'s valuation metrics:

The free-float of a company is the portion of its outstanding shares that are available for trading. Unfortunately, Mylan N.V.'s free-float is not available in the provided data.

The yield of a company's stock is the return an investor can expect to earn in the form of dividends. As of 2024, Mylan N.V.'s yield is 4.49%, while in 2025 it's expected to be 4.61%.

The new company, Viatris, plans to start returning capital to shareholders with a dividend of about 25% of free cash flow beginning the first full quarter after the deal closes.

This is a significant aspect of the valuation and repayment plan, indicating a focus on rewarding investors for their loyalty and investment.

Pro forma 2020 adjusted EBITDA is expected to be in the range of $7.5 billion to $8 billion, which will be used to fund this dividend and other repayment efforts.

The company aims to return capital to investors, making it an attractive option for those looking for a steady income stream.

The dividend will be paid out of free cash flow, ensuring that the company has the necessary funds to maintain its operations and make timely payments.

By returning a significant portion of its earnings to shareholders, Viatris is demonstrating its commitment to creating value for its investors.